Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia

Publication date: Available online 22 October 2015 Source:Best Practice & Research Clinical Haematology Author(s): Anjali Advani Using a case study of a 57-year-old man with relapsed/refractory precursor-B (pre-B) acute lymphoblastic leukemia (ALL), this review discusses treatment with immunoconjugates and autologous therapy in acute ALL. Three therapies—blinatumomab, inotuzumab, and CAR T cells—are considered here, each with advantages in specific clinical situations. These therapies represent some of the exciting advances that have been made in the treatment of ALL over the last several years.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research